Herticad®
Trastuzumab injection 440 mg
Trastuzumab biosimilar is a recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) that has been shown to inhibit the proliferation of HER2 overexpressing cancer cells
Indication: It is used in MBC or EBC patients who have tumours with either overexpression of HER2 or HER2 gene amplification in:
- Metastatic Breast Cancer (MBC)
- Early Breast Cancer (EBC)
- Metastatic Gastric Cancer (MGC)
Dosage and Administration : For intravenous (IV) infusion only. Do not administer as an IV push or bolus
Composition : Each vial contains lyophilised powder to be reconstituted
- The first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation
- Biosimilar Quality : Similarity proven based on assured quality, safety, & efficacy evidence
- Manufactured in world class PIC/s approved plant in Russia
- 225 patients Global trial data presented in ESMO 2016 Congress showed that Herticad and the innovator had equivalent Efficacy, Safety & Immunogenicity
For more information regarding Herticad®, please contact your local sales representative or email us at info@sayretherapeutics.com
